辉瑞溢价近44%购基石药业(02616.HK)近1.2亿股 签订合作协议
基石药业(02616.HK)公布,与辉瑞(PFE.US)的全资附属公司Pfizer Corporation订立股份认购协议,公司将向其配发及发行1.16亿股新股份,占公司扩大後股本9.9%。认购价每股13.37元,较上一个交易日收市价溢价43.8%。
同日公司与Pfizer Investment订立合作协议,双方将进行CS1001合作,公司已同意授予Pfizer Investment独家许可,以在中国商业化CS1001。双方亦将进行合作,同意合作开发及商业化合作地区内的额外资产及授权资产。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.